Health Care & Life Sciences » Pharmaceuticals | Dicerna Pharmaceuticals Inc.

Dicerna Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
184.00
295.00
2,277.00
6,176
Cost of Goods Sold (COGS) incl. D&A
523.00
848.00
-
-
-
-
Gross Income
523.00
848.00
-
-
-
-
SG&A Expense
16,855.00
44,253.00
62,484.00
59,203.00
62,086.00
66,622
EBIT
17,378.00
45,101.00
63,027.00
-
60,587.00
61,220
Unusual Expense
192.00
2,702.00
-
-
-
29,735
Interest Expense
952.00
199.00
-
-
-
-
Pretax Income
18,518.00
47,939.00
62,839.00
59,513.00
60,048.00
88,853
Consolidated Net Income
18,639.00
47,939.00
62,839.00
59,513.00
60,048.00
88,853
Net Income
18,639.00
47,939.00
62,839.00
59,513.00
60,048.00
88,853
Net Income After Extraordinaries
18,639.00
47,939.00
62,839.00
59,513.00
60,048.00
88,853
Net Income Available to Common
20,906.00
48,143.00
62,839.00
59,513.00
80,140.00
88,853
EPS (Basic)
1.19
3.00
3.09
2.87
3.66
1.60
Basic Shares Outstanding
17,527.70
16,070.10
20,320.60
20,719.80
21,917.40
55,616.10
EPS (Diluted)
1.19
3.00
3.09
2.87
3.66
1.60
Diluted Shares Outstanding
17,527.70
16,070.10
20,320.60
20,719.80
21,917.40
55,616.10
EBITDA
16,855.00
44,253.00
62,300.00
58,908.00
59,809.00
60,446
Non-Operating Interest Income
4.00
63.00
188.00
235.00
539.00
2,102
Other After Tax Income (Expense)
121.00
-
-
-
-
-
Preferred Dividends
2,267.00
204.00
-
-
20,092.00
-

About Dicerna Pharmaceuticals

View Profile
Address
87 Cambridgepark Drive
Cambridge Massachusetts 02140
United States
Employees -
Website http://www.dicerna.com
Updated 07/08/2019
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases using its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.